Therapeutic vaccines against chronic hepatitis-B virus and related complications
Sheikh Mohammad Fazle Akbar
Toshiba General Hospital, Japan

With the advent of novel insights about pathogenesis of chronic hepatitis-B (CHB) and realizing the limitations of commercially available antiviral drugs for CHB, new, novel and evidence based therapeutic approaches using hepatitis-B virus (HBV) related antigens (Therapeutic Vaccines) have been accomplished in CHB patients during last two decades. Therapeutic vaccines for CHB patients have been composed of different HBV related antigens with different forms of adjuvants and stimulants. Also, therapeutic vaccines have been administered in CHB patients by different routes and for variable durations. The safety profiles of therapeutic vaccines and their efficacies would be discussed for designing acceptable regimen of this new and novel mode of immune therapy for CHB patients.

Biography
Sheikh Mohammad Fazle Akbar has graduated in Medicine and Surgery from Bangladesh in 1980 and received his PhD in Medical Sciences from Japan in 1993. Being a post-graduate fellow from 1994-1996, he has worked as full Faculty Member at the Graduate School of Medicine, Ehime University, Japan from 1996-2008. In 2008, he has joined Toshiba General Hospital, Tokyo, Japan as Principal Investigator. He has worked to elucidate pathogenesis of chronic liver diseases and hepatocellular carcinoma; subsequently developed therapeutic vaccine for HBV transgenic mice and presently he has been conducting pilot studies and clinical trials in patients with CHB with Therapeutic Vaccines for last one decade to optimize a safe, effective and clinical viable regimen of this approach in CHB patients. He has authored more than one hundred scientific articles in peer reviewed journals.

Notes: